Sawicki GS[au] - Search Results

Year	Number of Results
2005	3
2006	3
2007	5
2008	9
2009	8
2010	8
2011	12
2012	12
2013	8
2014	11
2015	24
2016	13
2017	22
2018	21
2019	19
2020	13
2021	28
2022	14

1

Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries.

Volkova N, Moy K, Evans J, Campbell D, Tian S, Simard C, Higgins M, Konstan MW, Sawicki GS, Elbert A, Charman SC, Marshall BC, Bilton D. Volkova N, et al. Among authors: sawicki gs. J Cyst Fibros. 2020 Jan;19(1):68-79. doi: 10.1016/j.jcf.2019.05.015. Epub 2019 Jun 10. J Cyst Fibros. 2020. PMID: 31196670 Free article.

2

The Transition Readiness Assessment Questionnaire (TRAQ): its factor structure, reliability, and validity.

Wood DL, Sawicki GS, Miller MD, Smotherman C, Lukens-Bull K, Livingood WC, Ferris M, Kraemer DF. Wood DL, et al. Among authors: sawicki gs. Acad Pediatr. 2014 Jul-Aug;14(4):415-22. doi: 10.1016/j.acap.2014.03.008. Acad Pediatr. 2014. PMID: 24976354

3

Tribulations and (clinical) trials in cystic fibrosis.

Cagnina RE, Sawicki GS. Cagnina RE, et al. Among authors: sawicki gs. J Cyst Fibros. 2021 Mar;20(2):188-190. doi: 10.1016/j.jcf.2020.12.017. Epub 2021 Jan 3. J Cyst Fibros. 2021. PMID: 33408059 No abstract available.

4

Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.

Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE; VX14-661-110 study group. Flume PA, et al. Among authors: sawicki gs. Lancet Respir Med. 2021 Jul;9(7):733-746. doi: 10.1016/S2213-2600(20)30510-5. Epub 2021 Feb 10. Lancet Respir Med. 2021. PMID: 33581080

5

Extracting electricity with exosuit braking.

Riemer R, Nuckols RW, Sawicki GS. Riemer R, et al. Among authors: sawicki gs. Science. 2021 May 28;372(6545):909-911. doi: 10.1126/science.abh4007. Science. 2021. PMID: 34045341 No abstract available.

6

Men's health in the modern era of cystic fibrosis.

Khan FN, Tangpricha V, Hughan KS, Jain R, Ladores SL, Taylor-Cousar JL, West NE, Montemayor K, Sawicki GS, Uluer A, Aitken ML, Shnorhavorian M, Bray LA, Kvam C, Stalvey M, Kazmerski TM. Khan FN, et al. Among authors: sawicki gs. J Cyst Fibros. 2021 Nov;20(6):e121-e123. doi: 10.1016/j.jcf.2020.12.013. Epub 2020 Dec 26. J Cyst Fibros. 2021. PMID: 33376059 No abstract available.

7

Overcoming psychosocial challenges in cystic fibrosis: Promoting resilience.

Muther EF, Polineni D, Sawicki GS. Muther EF, et al. Among authors: sawicki gs. Pediatr Pulmonol. 2018 Nov;53(S3):S86-S92. doi: 10.1002/ppul.24127. Epub 2018 Jul 6. Pediatr Pulmonol. 2018. PMID: 29979497 Review.

8

The exoskeleton expansion: improving walking and running economy.

Sawicki GS, Beck ON, Kang I, Young AJ. Sawicki GS, et al. J Neuroeng Rehabil. 2020 Feb 19;17(1):25. doi: 10.1186/s12984-020-00663-9. J Neuroeng Rehabil. 2020. PMID: 32075669 Free PMC article. Review.

9

Exoskeletons Improve Locomotion Economy by Reducing Active Muscle Volume.

Beck ON, Punith LK, Nuckols RW, Sawicki GS. Beck ON, et al. Among authors: sawicki gs. Exerc Sport Sci Rev. 2019 Oct;47(4):237-245. doi: 10.1249/JES.0000000000000204. Exerc Sport Sci Rev. 2019. PMID: 31436749 Review.

10

Cystic fibrosis patient registries: A valuable source for clinical research.

Dasenbrook EC, Sawicki GS. Dasenbrook EC, et al. Among authors: sawicki gs. J Cyst Fibros. 2018 Jul;17(4):433-440. doi: 10.1016/j.jcf.2018.03.001. Epub 2018 Mar 16. J Cyst Fibros. 2018. PMID: 29555479 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results